Literature DB >> 19474648

Additional HIV-1 mutation patterns associated with reduced phenotypic susceptibility to etravirine in clinical samples.

Ron M Kagan1, Prakash Sista, Theresa Pattery, Lee Bacheler, Dale A Schwab.   

Abstract

We investigated the phenotypic impact of a number of uncommon amino acid substitutions at HIV-1 reverse transcriptase positions 103 and 138, which are not part of the etravirine resistance score and were found in combination with the high-impact mutation K101P. Etravirine phenotypic fold changes were 380-1400 for K101P + E138A/G/Q + K103N/S/T + V179I and 12-130 for K101P + (K103S +/- V179I) in the absence of E138A/G/Q. Although the effect of K103S is unclear, additional position 138 substitutions seem important for etravirine susceptibility.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474648     DOI: 10.1097/QAD.0b013e32832d8771

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  3 in total

1.  Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.

Authors:  Adele L McCormick; Chris M Parry; Anne Crombe; Ruth L Goodall; Ravindra K Gupta; Pontiano Kaleebu; Cissy Kityo; Michael Chirara; Greg J Towers; Deenan Pillay
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.

Authors:  Almoustapha Issiaka Maïga; Diane Descamps; Laurence Morand-Joubert; Isabelle Malet; Anne Derache; Mamadou Cisse; Victoria Koita; Alain Akonde; Bah Diarra; Marc Wirden; Anatole Tounkara; Yvan Verlinden; Christine Katlama; Dominique Costagliola; Bernard Masquelier; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

3.  Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy.

Authors:  Tong Wang; Younong Xu; Haiying Zhu; Thomas Andrus; Sergei B Ivanov; Charlotte Pan; Jazel Dolores; Gregory C Dann; Michael Zhou; Dominic Forte; Zihuan Yang; Sarah Holte; Lawrence Corey; Tuofu Zhu
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.